---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-033068"
form_type: "8-K"
ticker: "IVVD"
cik: "0001832038"
company_name: "Invivyd, Inc."
filed_at: "2025-03-05T23:59:59+00:00"
generated_at: "2026-05-25T11:15:18.801178+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Invivyd reports PEMGARDA neutralizes dominant SARS-CoV-2 variant LP.8.1

## Summary
- New in vitro data show PEMGARDA (pemivibart) neutralizes dominant LP.8.1 variant, consistent with prior variants.
- CDC reports LP.8.1, XEC, and KP.3.1.1 make up majority of U.S. cases; all susceptible to PEMGARDA.
- Pemivibart activity remains within expected assay variability range since Omicron BA.2.
- Data provided to U.S. FDA; update to PEMGARDA Fact Sheet for Healthcare Providers anticipated.
- VYD2311, next-gen mAb candidate, also demonstrates neutralizing activity against LP.8.1.

## SEC filing metadata
- accession: 0000950170-25-033068
- form_type: 8-K
- ticker: IVVD
- cik: 0001832038
- company_name: Invivyd, Inc.
- filed_at: 2025-03-05T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1832038/000095017025033068/0000950170-25-033068-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1832038/000095017025033068/ivvd-20250305.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-033068
- JSON: https://secwatch.observer/filing/0000950170-25-033068.json
- Plain text: https://secwatch.observer/filing/0000950170-25-033068.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.